Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination

Simple item page
dc.contributor.authorTong, X.
dc.contributor.authorMcNamara, R. P.
dc.contributor.authorAvendano, M. J.
dc.contributor.authorSerrano, E. F.
dc.contributor.authorGarcia-Salum, T.
dc.contributor.authorPardo-Roa, C.
dc.contributor.authorBertera, H. L.
dc.contributor.authorChicz, T. M.
dc.contributor.authorLevican, J.
dc.contributor.authorPoblete, E.
dc.contributor.authorSalinas, E.
dc.contributor.authorMunoz, A.
dc.contributor.authorRiquelme, A.
dc.contributor.authorAlter, G.
dc.contributor.authorMedina, R. A.
dc.date.accessioned2024-01-31T14:30:14Z
dc.date.available2024-01-31T14:30:14Z
dc.date.issued2023
dc.description.abstractEfficiency of SARS-CoV-2 vaccines has long been attributed to the neutralising capacity of the antibodies that are produced upon prime-boost vaccinations. Here authors show that upon vaccination with CoronaVac and BNT162b2 vaccines in prime-boost regimens, antibodies with Fc-effector functions to enhance cellular and innate immunity are also produced, albeit with different kinetics., Since the emergence of SARS-CoV-2, vaccines targeting COVID-19 have been developed with unprecedented speed and efficiency. CoronaVac, utilising an inactivated form of the COVID-19 virus and the mRNA26 based Pfizer/BNT162b2 vaccines are widely distributed. Beyond the ability of vaccines to induce production of neutralizing antibodies, they might lead to the generation of antibodies attenuating the disease by recruiting cytotoxic and opsonophagocytic functions. However, the Fc-effector functions of vaccine induced antibodies are much less studied than virus neutralization. Here, using systems serology, we follow the longitudinal Fc-effector profiles induced by CoronaVac and BNT162b2 up until five months following the two-dose vaccine regimen. Compared to BNT162b2, CoronaVac responses wane more slowly, albeit the levels remain lower than that of BNT162b2 recipients throughout the entire observation period. However, mRNA vaccine boosting of CoronaVac responses, including response to the Omicron variant, induce significantly higher peak of antibody functional responses with increased humoral breadth. In summary, we show that vaccine platform-induced humoral responses are not limited to virus neutralization but rather utilise antibody dependent effector functions. We demonstrate that this functionality wanes with different kinetics and can be rescued and expanded via boosting with subsequent homologous and heterologous vaccination.
dc.description.funderLeonardo Almonacid at Unidad de Bioinformatica y Biologia Computacional Pontificia Universidad Catolica de Chile
dc.format.extent14 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1038/s41467-023-39189-8
dc.identifier.eisbn978-3-030-28856-3
dc.identifier.eissn2041-1723
dc.identifier.isbn978-3-030-28855-6
dc.identifier.issn20476310 20476302
dc.identifier.pubmedid36222077
dc.identifier.scopusidSCOPUS_ID:85140058619
dc.identifier.urihttps://doi.org/10.1038/s41467-023-39189-8
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/81134
dc.identifier.wosidWOS:001030405300013
dc.information.autorucFacultad de Medicina; Pardo Roa, Catalina; S/I; 225251
dc.issue.numero1
dc.language.isoen
dc.nota.accesoSin adjunto
dc.pagina.final318
dc.pagina.inicio305
dc.publisherSPRINGER INTERNATIONAL PUBLISHING AG
dc.relation.ispartofPediatric Obesity
dc.revistaNATURE COMMUNICATIONS
dc.rightsregistro bibliográfico
dc.subjectAvian Influenza virus
dc.subjectInfluenza A Virus
dc.subjectH5N1 Subtype
dc.subjectWild birds
dc.subjectViral dissemination
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleWaning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
dc.typeartículo
dc.volumen14
sipa.codpersvinculados225251
sipa.indexWOS
sipa.trazabilidadCarga SIPA;31-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination.pdf
Size:
2.22 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas